ArticleCase reports in oncology
Severe Hypercalcemia in a Patient with Chronic Lymphocytic Leukemia following Treatment Disruption.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypercalcemia is a common paraneoplastic syndrome rarely seen in chronic lymphocytic leukemia (CLL). When it occurs, it often signals disease progression or Richter transformation. Disruption of cancer care in conflict zones may contribute to worsening clinical outcomes. Case Presentation: We report a 63-year-old Arab female with a 3-year history of CLL, previously treated with chlorambucil and rituximab, who developed severe hypercalcemia (total calcium 19.9 mg/dL) after an 8-month interruption of chemotherapy due to transportation barriers amid regional conflict. She presented with confusion, weakness, polyuria, and polydipsia. Laboratory evaluation showed suppressed parathyroid hormone, normal vitamin D, renal impairment, and no evidence of lytic bone lesions. Treatment with intravenous fluids, calcitonin, and zoledronic acid effectively lowered calcium levels. Despite reinitiation of chemotherapy, she later developed fatal febrile neutropenia and septic shock. Conclusion: This case highlights a rare but serious complication of CLL and underscores the detrimental impact of healthcare disruption on disease progression and outcomes. Clinicians should maintain vigilance for hypercalcemia in hematologic malignancies, even during remission, and prioritize continuity of care in vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.